Shire Pharmaceuticals Group plc
Hampshire International Business Park
About Shire Pharmaceuticals Group plcShire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its first two years of operation, the company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter, innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer's disease and end-stage renal failure.
By 1992, Shire had embarked on the first of what would be a series of strategic acquisitions -- these were bold ventures that fortified our product lines and underscored the wisdom of a business model focused exclusively on products sold to specialist physicians. After the turn of the millennium, with the acquisition of TKT, we began our focus on rare diseases, something that remains a strategic focus for the company today. The Shire pipeline continues to be sustained by creative acquisitions and innovative licensing deals. Smart commercialization strategies have ensured that the right patients and the right physicians have the information they need to make appropriate choices about treatment options.
In June 2016, Shire completed a combination with Baxalta, creating the world’s leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. With over 22,000 employees across more than 100 countries, Shire’s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs.
FOUNDER: Harry Stratford
CEO: Flemming Ornskov
CFO: Jeffrey Poulton
Please click here for Shire job opportunities..
Please click here for clinical trial information..
Please click here for product information..
Tweets by Shire
459 articles with Shire Pharmaceuticals Group plc
In May, the company sold off assets worth $5.7 billion and now, the company is looking to sell more.
The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda's strategy to pare down debt from its $62 billion acquisition of Shire.
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
On Tuesday, Takeda Pharmaceutical finally wrapped up its $62 billion acquisition of Shire plc. As the combined companies continue to merge and shape their combined roles, Chief Executive Officer Christophe Weber is already eying potential deals to offset some of the debt the company garnered.
1/8/2019Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.
After announcing a potential snag with the European Commission last month, Takeda said this morning that it received clearance for its acquisition of Shire. The clearance is conditional on addressing overlaps in the companies’ inflammatory bowel disease businesses.
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
Updated: Mirum Pharmaceuticals Launches With Phase III-Ready Drug From Shire, $120 Million in Fin...
11/7/2018Based in San Diego, Mirum entered into the agreement with Shire for the exclusive global rights to develop and market maralixibat, a Phase II oral inhibitor of the apical sodium-dependent bile acid transporter (ASBT).
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
Berkeley Lights calls itself a digital cell biology company. It develops and markets tech platforms for what it calls “the intersection of biology, technology and information.”
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), basically a rejection, to Netherlands-based Pharming Group for its supplemental Biologics License Application (sBLA) for Ruconest.
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
One day after it was revealed Takeda is moving its U.S. headquarters from Illinois to Boston ahead of the completion of the Shire Plc acquisition, the Japanese company is reportedly considering the sale of Shire’s eye-care business in order to cut some debt incurred from funding the $62 billion d...
Takeda Pharmaceuticals will shutter its Deerfield, Ill. U.S. headquarters and move the operations to Boston as the company consolidates its operations following the $62 billion acquisition of Shire.
The opposition to Takeda Pharmaceutical acquiring Shire has taken on another dimension with a prominent member of the family that created the Japanese pharmaceutical company speaking publicly against the deal.